Seasoned Life Sciences Executive Joins to Lead Operations and Scale Lahjavida’s Dye-Drug Conjugate Platform COLORADO ...

BioNTech and partner DualityBio are accelerating the development of their B7-H3 antibody-drug conjugate into a phase 3 trial for metastatic castration-resistant prostate cancer (mCRPC). | BioNTech and ...

Discusses MissionEB Phase III Trial and CORDStrom as a Disease-Modifying Therapy for RDEB February 26, 2026 1:00 PM ...

PROSERA Study Overview and Baseline Characteristics ...

In an era of overt sexism in the sciences, she made two major discoveries, including identifying a chemical signal in the ...

India faces a growing crisis in wound treatment, driven by diabetes and an ageing population. A new policy approach could ...

San Diego-based Gossamer Bio released long-awaited Phase 3 data today for its drug seralutinib, revealing a complex set of results that both challenged and encouraged researchers. The PROSERA study, ...

Q4 2025 Earnings Call February 26, 2026 4:30 PM ESTCompany ParticipantsMike Brophy - Chief Financial OfficerSteve Chapman - CEO ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech ...

JS207, Junshi Biosciences’ independently developed recombinant humanized anti-PD-1/VEGF bispecific antibody, has demonstrated promising anti-tumor activity and a manageable safety profile in both ...

"My gym teacher picked a kid up by his unusually large ears. Nobody cared because it was the '80s." View Entire Post › ...

Gilead Sciences, Inc. today announced that it has entered into a definitive agreement to acquire Arcellx for $115 per share in cash at closing and one contingent value right of $5 per share, which ...